-

SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Class Action Against C3.ai, Inc.

SAN DIEGO--(BUSINESS WIRE)--The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired C3,ai, Inc. (NYSE: AI): (a) common stock pursuant to the Company's December 9, 2020 initial public offering ("IPO"); or (b) securities between December 9, 2020 and February 15, 2022, for violations of the Securities Exchange Act of 1934. C3.ai operates as an enterprise artificial intelligence ("AI") software company.

If you would like more information about C3.ai, Inc.'s misconduct, click here.

What is this Case About: C3.ai, Inc. (AI) Makes False and Misleading Statements in its Offering Documents in Support of its IPO

According to the complaint, C3.ai went public on December 9, 2020, offering shares at $42.00 per share. Defendants - in the Offering Documents in support of the Company's IPO and during the class period - touted the Company's relationships with technology leaders, including Baker Hughes, and its "large and rapidly growing [total addressable] market," among other things.

However, these statements were false and misleading. Specifically, defendants and the Offering Documents failed to disclose that: (i) C3.ai's partnership with Baker Hughes was deteriorating and that the Company employed a flawed accounting methodology to conceal the deterioration of the partnership, (ii) C3.ai faced challenges in product adoption and significant salesforce turnover; and (iii) C3.ai overstated, inter alia, the extent of its investment in technology, description of its customers, its total addressable market, the pace of its growth, and the scale of alliances with its major business partners.

On February 22, 2022, Spruce Point Capital Management issued a report alleging it had uncovered "[e]vidence of a severely challenged partnership with Baker Hughes, a related party and C3ai's largest customer" and "[s]igns of problematic financial reporting and accounting regarding the Baker Hughes joint venture and a revolving door in C3.ai's Chief Financial Officer position." The report further detailed, "[c]hallenges in product adoption and significant salesforce turnover make it unlikely that C3.ai will meet aggressive analyst estimates," as well as "[w]orrisome corporate governance practices and insider enrichment." On this news, C3.ai's stock price fell $1.01 per share, or almost 4%, on February 16, 2022. The stock trades significantly below the offering price of $42.00 per share.

Next Steps: If you acquired shares of C3.ai, Inc. (AI) pursuant to the Company's IPO or between December 9, 2020 and February 15, 2022, you have until May 3, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Informat5/3/22ion Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against C3.ai, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:AI

Release Summary
C3.ai, Inc. (AI) Makes False and Misleading Statements in its Offering Documents in Support of its IPO
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom